Inner workings of a cellular nanomotor revealed
Our cells produce thousands of proteins, but more than one-third of these proteins can fulfill their function only after migrating to the outside of the cell. While it is known that protein migration occurs with the help of various ‘nanomotors’ that push proteins out of the cell, little is known about their precise mechanical functioning. New research by Anastassios Economou (Laboratory of Molecular Bacteriology - Rega Institute) and his team reveals the inner workings of one such nanomotor, called SecA, with new clarity.
In this rendering of the SecA nanomotor, the two pistons (coloured cyan and light green) await the arrival of a protein. Cylinders, arrows and loops make up the nanomotor’s mechanical parts
© T. Economou
Protein migration is a fundamental problem in biology and is essential for life. Examples of migrating proteins include insulin (the absence of which leads to diabetes), antibodies (essential for combating infections), membrane channels (essential for neuronal cell function) and toxin-proteins (secreted by pathogenic microorganisms).
Migrating proteins contain chemical signals called signal peptides. These signal peptides act as postal addresses and direct exported proteins to the membrane for transport outside the cell.
In previous research, Dr Economou, in collaboration with Babis Kalodimos (Rutgers University), revealed how signal peptides bind to a specific cellular receptor on the membrane, which subsequently connects to the export channel leading out of the cell. This receptor was also found to act as a nanomotor, with two separate piston-like mechanical parts that somehow push proteins out of the cell. The exact mechanism by which this occurred remained a mystery. Until now.
Finely orchestrated
In the current study, published in Molecular Cell, Economou and his team show how the SecA receptor moves to push proteins out of the cell: when a signal peptide makes contact, the two pistons become excited. They position themselves one against the other in a series of defined steps and modify their shape. This finely orchestrated series of motions opens the export channel and traps the exported protein inside it. In a final step, the two parts dissociate and the remaining single piston pushes the protein out in cycles of repeated motions.
The discovery adds a significant piece in the puzzle of exploiting protein migration to improve health. “Moving forward, this discovery will help us focus efforts to find specific antibiotics against harmful bacterial protein secretion pathways,” says Dr Economou. “It also offers the possibility to optimise biotechnological production of human biopharmaceuticals by using microbial ‘cell factories’ for secreting biopharmaceuticals.We will be pursuing these avenues in future research.”
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
